OBJECTIVE: We investigated the use of immunostaining with antibodies to tau, ubiquitin, and alpha B-crystallin in defining a protocol for the staged neuropathologic examination of brains from patients with a progressive frontotemporal dementia. DESIGN: Brains obtained from 50 patients dying with the clinical diagnosis of frontotemporal dementia were examined histopathologically to define pathologic distinctions. SETTING: Two university hospital neuropathology departments. RESULTS: Anti-tau immunostaining defined corticobasal degeneration, Alzheimer's disease, and Pick's disease; antiubiquitin defined motor neuron disease with dementia. The remaining brains have frontal lobe degeneration: the use of alpha B-crystallin immunostaining, on these, to detect ballooned neurons may help to define two groups of patients, one of which we believe may represent a variant of Pick's disease. CONCLUSION: These findings indicate that immunostaining with these antibodies is essential for the evaluation of frontal dementia.
OBJECTIVE: We investigated the use of immunostaining with antibodies to tau, ubiquitin, and alpha B-crystallin in defining a protocol for the staged neuropathologic examination of brains from patients with a progressive frontotemporal dementia. DESIGN: Brains obtained from 50 patients dying with the clinical diagnosis of frontotemporal dementia were examined histopathologically to define pathologic distinctions. SETTING: Two university hospital neuropathology departments. RESULTS: Anti-tau immunostaining defined corticobasal degeneration, Alzheimer's disease, and Pick's disease; antiubiquitin defined motor neuron disease with dementia. The remaining brains have frontal lobe degeneration: the use of alpha B-crystallin immunostaining, on these, to detect ballooned neurons may help to define two groups of patients, one of which we believe may represent a variant of Pick's disease. CONCLUSION: These findings indicate that immunostaining with these antibodies is essential for the evaluation of frontal dementia.
Authors: R L Davis; P D Holohan; A E Shrimpton; A H Tatum; J Daucher; G H Collins; R Todd; C Bradshaw; P Kent; D Feiglin; A Rosenbaum; M S Yerby; C M Shaw; F Lacbawan; D A Lawrence Journal: Am J Pathol Date: 1999-12 Impact factor: 4.307
Authors: Julia Terreros-Roncal; Miguel Flor-García; Elena P Moreno-Jiménez; Noemí Pallas-Bazarra; Alberto Rábano; Nirnath Sah; Henriette van Praag; Damiana Giacomini; Alejandro F Schinder; Jesús Ávila; Maria Llorens-Martín Journal: J Neurosci Date: 2019-05-27 Impact factor: 6.167
Authors: Nigel J Cairns; Eileen H Bigio; Ian R A Mackenzie; Manuela Neumann; Virginia M-Y Lee; Kimmo J Hatanpaa; Charles L White; Julie A Schneider; Lea Tenenholz Grinberg; Glenda Halliday; Charles Duyckaerts; James S Lowe; Ida E Holm; Markus Tolnay; Koichi Okamoto; Hideaki Yokoo; Shigeo Murayama; John Woulfe; David G Munoz; Dennis W Dickson; Paul G Ince; John Q Trojanowski; David M A Mann Journal: Acta Neuropathol Date: 2007-06-20 Impact factor: 17.088
Authors: Keith A Josephs; John R Hodges; Julie S Snowden; Ian R Mackenzie; Manuela Neumann; David M Mann; Dennis W Dickson Journal: Acta Neuropathol Date: 2011-05-26 Impact factor: 17.088